董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anne Marie Graffin | 女 | Member of the Supervisory Board | 59 | 未披露 | 未持股 | 2021-03-23 |
| Frederic Grimaud | 男 | Chairman of the Supervisory Board | 56 | 未披露 | 未持股 | 2021-03-23 |
| James Sulat | 男 | Vice Chairman of the Supervisory Board | 70 | 未披露 | 未持股 | 2021-03-23 |
| Johanna Willemina Pattenier | 女 | Member of the Supervisory Board | 61 | 未披露 | 未持股 | 2021-03-23 |
| Sharon Tetlow | 女 | Member of the Supervisory Board | 61 | 未披露 | 未持股 | 2021-03-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas Lingelbach | 男 | Chairman of the Management Board, President, Chief Executive Officer | 58 | 未披露 | 未持股 | 2021-03-23 |
| Franck Grimaud | 男 | President, Chief Business Officer | 54 | 未披露 | 未持股 | 2021-03-23 |
| Juan Carlos Jaramillo | 男 | Chief Medical Officer | 50 | 未披露 | 未持股 | 2021-03-23 |
| Frederic Jacotot | 男 | General Counsel, Corporate Secretary | 56 | 未披露 | 未持股 | 2021-03-23 |
董事简历
中英对照 | 中文 | 英文- Anne Marie Graffin
-
Anne Marie Graffin自2013年起担任监事会成员，自2017年起担任任命与薪酬委员会主席，自2017年7月起担任监事会副主席。她自2013年起担任Valneva SE Nantes，FR-Vienna的非执行董事会成员，自2015年起担任Sartorius Stedim Biotech SA（Aubagne，FR-GO&235；TTingen，GER）的非执行董事会成员。Graffin女士拥有开发市场准入战略和推动生物技术公司增长的专业知识。她自2011年起担任制药行业顾问，在创新和初创企业领域开发了许多举措，将生物技术和MedTech初创企业与欧盟主要风险投资公司和投资者联系起来。此前，她曾担任赛诺菲巴斯德公司（Sanofi Pasteur MSD）的Vice President，该公司是欧洲疫苗领域的领导者，并担任执行委员会成员。任职Sanofi Pasteur MSD公司之前，她曾任职Roc公司5年，担任国际品牌经理。Graffin女士毕业于巴黎ESSEC商学院。
Anne Marie Graffin has served as a supervisory board member since 2013 as chairwoman of the appointments and compensation committee since 2017 and as Vice Chairwoman of the supervisory board since July 2017. She has over 20 years of experience in life sciences and pharmaceutical companies. She has served as a non-executive board member of Valneva SE Nantes, FR - Vienna, AT since 2013 and of Sartorius Stedim Biotech SA (Aubagne, FR - Goëttingen, Ger) since 2015. Ms. Graffin has expertise in both developing market access strategies and driving biotechnology companies' growth. She has been a consultant to the pharmaceutical industry since 2011 developing many initiatives within the innovation and startups fields, connecting biotech and medtech startups with major EU venture capital firms and investors. Previously, she was a vice president at Sanofi Pasteur MSD, a European leader in the vaccine field, and acted as a member of the Executive Committee. Prior to working at Sanofi Pasteur MSD, she worked for five years at ROC as international brand manager. Ms. Graffin graduated from ESSEC Business School Paris. - Anne Marie Graffin自2013年起担任监事会成员，自2017年起担任任命与薪酬委员会主席，自2017年7月起担任监事会副主席。她自2013年起担任Valneva SE Nantes，FR-Vienna的非执行董事会成员，自2015年起担任Sartorius Stedim Biotech SA（Aubagne，FR-GO&235；TTingen，GER）的非执行董事会成员。Graffin女士拥有开发市场准入战略和推动生物技术公司增长的专业知识。她自2011年起担任制药行业顾问，在创新和初创企业领域开发了许多举措，将生物技术和MedTech初创企业与欧盟主要风险投资公司和投资者联系起来。此前，她曾担任赛诺菲巴斯德公司（Sanofi Pasteur MSD）的Vice President，该公司是欧洲疫苗领域的领导者，并担任执行委员会成员。任职Sanofi Pasteur MSD公司之前，她曾任职Roc公司5年，担任国际品牌经理。Graffin女士毕业于巴黎ESSEC商学院。
- Anne Marie Graffin has served as a supervisory board member since 2013 as chairwoman of the appointments and compensation committee since 2017 and as Vice Chairwoman of the supervisory board since July 2017. She has over 20 years of experience in life sciences and pharmaceutical companies. She has served as a non-executive board member of Valneva SE Nantes, FR - Vienna, AT since 2013 and of Sartorius Stedim Biotech SA (Aubagne, FR - Goëttingen, Ger) since 2015. Ms. Graffin has expertise in both developing market access strategies and driving biotechnology companies' growth. She has been a consultant to the pharmaceutical industry since 2011 developing many initiatives within the innovation and startups fields, connecting biotech and medtech startups with major EU venture capital firms and investors. Previously, she was a vice president at Sanofi Pasteur MSD, a European leader in the vaccine field, and acted as a member of the Executive Committee. Prior to working at Sanofi Pasteur MSD, she worked for five years at ROC as international brand manager. Ms. Graffin graduated from ESSEC Business School Paris.
- Frederic Grimaud
-
Frederic Grimaud，2012年12月起，担任本公司监事会主席。Grimaud先生从2001年9月开始一直担任Groupe Grimaud La Corbi&232；re SA的总裁兼首席执行官，这是一家生命科学开发公司，也是我司最大的股东，在此之前，在Groupe Grimaud及其关联公司担任多个职位。
Frederic Grimaud has served as Chairman of our Supervisory Board since December 2012. Mr. Grimaud has served as President and Chief Executive Officer of Groupe Grimaud La Corbière SA, a life sciences development company and our largest shareholder, since September 2001 and prior to that held various positions at Groupe Grimaud and its affiliates. - Frederic Grimaud，2012年12月起，担任本公司监事会主席。Grimaud先生从2001年9月开始一直担任Groupe Grimaud La Corbi&232；re SA的总裁兼首席执行官，这是一家生命科学开发公司，也是我司最大的股东，在此之前，在Groupe Grimaud及其关联公司担任多个职位。
- Frederic Grimaud has served as Chairman of our Supervisory Board since December 2012. Mr. Grimaud has served as President and Chief Executive Officer of Groupe Grimaud La Corbière SA, a life sciences development company and our largest shareholder, since September 2001 and prior to that held various positions at Groupe Grimaud and its affiliates.
- James Sulat
-
James Sulat自2013年以来一直担任我们的监事会成员，目前是我们监事会的副主席。此前，他曾任职Intercell AG的监事会（从2005年到2013年公司与Vivalis SA合并）。从2009年到2013年，苏拉特先生担任Maxygen，Inc.的首席执行官兼首席财务官，并从2003年到2013年担任Maxygen’；的董事会成员。Sulat从2005年到2009年在Memory Pharmaceuticals Corp.担任多个职位，包括从2005年到2008年担任总裁和首席执行官，从2005年到2009年担任Memory&8217；s董事会成员。此前，苏拉特先生曾担任Chiron Corporation和Stanford Health Services的首席财务官。苏拉特先生自2015年以来一直担任Arch Therapeutics，Inc.的董事会成员，并于2014年至2020年11月担任AMAGPharmaceuticals，Inc.的董事会成员。Sulat先生在斯坦福大学（Stanford University）获得卫生服务管理工商管理硕士学位和硕士学位，并在耶鲁大学（Yale University）获得行政学学士学位。
James Sulat has served on our Supervisory Board since 2013 and is currently Vice Chairman of our Supervisory Board. Prior to that, he served on the Supervisory Board of Intercell AG from 2005 until its merger with Vivalis SA in 2013. From 2009 to 2013 Mr. Sulat served as Chief Executive Officer and Chief Financial Officer of Maxygen, Inc., and as a member of Maxygen’s Board of Directors from 2003 to 2013. From 2005 to 2009 Mr. Sulat served in a variety of roles at Memory Pharmaceuticals Corp., including as President and Chief Executive Officer from 2005 to 2008 and as a member of Memory’s Board of Directors from 2005 to 2009. Previously, Mr. Sulat served as Chief Financial Officer for Chiron Corporation and Stanford Health Services. Mr. Sulat has served on the Board of Directors of Arch Therapeutics, Inc. since 2015 and served on the Board of Directors of AMAG Pharmaceuticals, Inc. from 2014 to November 2020. Mr. Sulat received an MBA and an M.S. in Health Services Administration from Stanford University and a B.S. in Administrative Sciences from Yale University. - James Sulat自2013年以来一直担任我们的监事会成员，目前是我们监事会的副主席。此前，他曾任职Intercell AG的监事会（从2005年到2013年公司与Vivalis SA合并）。从2009年到2013年，苏拉特先生担任Maxygen，Inc.的首席执行官兼首席财务官，并从2003年到2013年担任Maxygen’；的董事会成员。Sulat从2005年到2009年在Memory Pharmaceuticals Corp.担任多个职位，包括从2005年到2008年担任总裁和首席执行官，从2005年到2009年担任Memory&8217；s董事会成员。此前，苏拉特先生曾担任Chiron Corporation和Stanford Health Services的首席财务官。苏拉特先生自2015年以来一直担任Arch Therapeutics，Inc.的董事会成员，并于2014年至2020年11月担任AMAGPharmaceuticals，Inc.的董事会成员。Sulat先生在斯坦福大学（Stanford University）获得卫生服务管理工商管理硕士学位和硕士学位，并在耶鲁大学（Yale University）获得行政学学士学位。
- James Sulat has served on our Supervisory Board since 2013 and is currently Vice Chairman of our Supervisory Board. Prior to that, he served on the Supervisory Board of Intercell AG from 2005 until its merger with Vivalis SA in 2013. From 2009 to 2013 Mr. Sulat served as Chief Executive Officer and Chief Financial Officer of Maxygen, Inc., and as a member of Maxygen’s Board of Directors from 2003 to 2013. From 2005 to 2009 Mr. Sulat served in a variety of roles at Memory Pharmaceuticals Corp., including as President and Chief Executive Officer from 2005 to 2008 and as a member of Memory’s Board of Directors from 2005 to 2009. Previously, Mr. Sulat served as Chief Financial Officer for Chiron Corporation and Stanford Health Services. Mr. Sulat has served on the Board of Directors of Arch Therapeutics, Inc. since 2015 and served on the Board of Directors of AMAG Pharmaceuticals, Inc. from 2014 to November 2020. Mr. Sulat received an MBA and an M.S. in Health Services Administration from Stanford University and a B.S. in Administrative Sciences from Yale University.
- Johanna Willemina Pattenier
-
Johanna Willemina Patenier自2020年6月起担任我们的监事会成员。Pattenier博士曾于2012年至2017年1月在Novartis AG担任多个职位，最近担任瑞士巴塞尔Novartis Vaccines and Diagnostics总经理。在此之前，Patenier博士曾在制药公司GlaxoSmithKline plc、Organon&Co.和Byk Gulden Lomberg Chemische Fabrik GmbH担任过各种商业和医疗职务。Pattenier博士获得了医学博士学位。在实验外科中，对洪堡/萨尔大学的朗格汉斯胰岛和伊拉斯谟大学的她的医学博士进行了冷冻保存。
Johanna Willemina Pattenier has served on our Supervisory Board since June 2020. Dr. Pattenier served in a variety of positions at Novartis AG from 2012 through January 2017 most recently as General Manager of Novartis Vaccines and Diagnostics in Basel, Switzerland. Prior to this, Dr. Pattenier held a variety of commercial and medical positions at pharmaceutical companies GlaxoSmithKline plc, Organon & Co. and Byk Gulden Lomberg Chemische Fabrik GmbH. Dr. Pattenier received her Ph.D Dr. Med. in experimental surgery, cryopreservation of islets of Langerhans from University of Homburg/Saar and her M.D. from Erasmus University. - Johanna Willemina Patenier自2020年6月起担任我们的监事会成员。Pattenier博士曾于2012年至2017年1月在Novartis AG担任多个职位，最近担任瑞士巴塞尔Novartis Vaccines and Diagnostics总经理。在此之前，Patenier博士曾在制药公司GlaxoSmithKline plc、Organon&Co.和Byk Gulden Lomberg Chemische Fabrik GmbH担任过各种商业和医疗职务。Pattenier博士获得了医学博士学位。在实验外科中，对洪堡/萨尔大学的朗格汉斯胰岛和伊拉斯谟大学的她的医学博士进行了冷冻保存。
- Johanna Willemina Pattenier has served on our Supervisory Board since June 2020. Dr. Pattenier served in a variety of positions at Novartis AG from 2012 through January 2017 most recently as General Manager of Novartis Vaccines and Diagnostics in Basel, Switzerland. Prior to this, Dr. Pattenier held a variety of commercial and medical positions at pharmaceutical companies GlaxoSmithKline plc, Organon & Co. and Byk Gulden Lomberg Chemische Fabrik GmbH. Dr. Pattenier received her Ph.D Dr. Med. in experimental surgery, cryopreservation of islets of Langerhans from University of Homburg/Saar and her M.D. from Erasmus University.
- Sharon Tetlow
-
Sharon Tetlow，自2022年3月起担任Structure Therapeutics公司董事会成员。自2016年1月以来，Tetlow女士担任Potrero Hill Advisors的管理合伙人，该公司是一家向生命科学公司提供战略和运营财务支持的咨询公司。在加入Potrero Hill Advisors之前，Tetlow女士在过去20年里担任过几家公共和私营生物技术公司的首席财务官。Tetlow女士目前在生物制药公司DICE Therapeutics, Inc.（Nasdaq：DICE）的董事会、提名和治理委员会以及审计委员会主席、生物制药公司Catalyst Biosciences, Inc.（Nasdaq：CBIO）的董事会以及审计委员会主席、Valneva SE（Nasdaq：VALN，EPA：VLA）的监事会以及审计委员会主席，Valneva SE是一家全球商业上市疫苗公司。Tetlow女士在特拉华大学获得心理学学士学位，在斯坦福大学获得工商管理硕士学位。
Sharon Tetlow,has served as a member of Structure Therapeutics Inc. board of directors since March 2022. Since January 2016, Ms. Tetlow has served as Managing Partner of Potrero Hill Advisors, an advisory firm providing strategic and operational financial support to life sciences companies. Prior to Potrero Hill Advisors, Ms. Tetlow served as chief financial officer of several public and private biotech companies for the previous twenty years. Ms. Tetlow currently serves on the board of directors, on the nominating and governance committee and as chair of the audit committee of DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company, on the board of directors and as chair of the audit committee of Catalyst Biosciences, Inc. (Nasdaq: CBIO), a biopharmaceutical company, and on the supervisory board and as chair of the audit committee of Valneva SE (Nasdaq: VALN, EPA: VLA), a global commercial stage, public vaccine company. Ms. Tetlow received her B.S. in Psychology from the University of Delaware and her M.B.A. from Stanford University. - Sharon Tetlow，自2022年3月起担任Structure Therapeutics公司董事会成员。自2016年1月以来，Tetlow女士担任Potrero Hill Advisors的管理合伙人，该公司是一家向生命科学公司提供战略和运营财务支持的咨询公司。在加入Potrero Hill Advisors之前，Tetlow女士在过去20年里担任过几家公共和私营生物技术公司的首席财务官。Tetlow女士目前在生物制药公司DICE Therapeutics, Inc.（Nasdaq：DICE）的董事会、提名和治理委员会以及审计委员会主席、生物制药公司Catalyst Biosciences, Inc.（Nasdaq：CBIO）的董事会以及审计委员会主席、Valneva SE（Nasdaq：VALN，EPA：VLA）的监事会以及审计委员会主席，Valneva SE是一家全球商业上市疫苗公司。Tetlow女士在特拉华大学获得心理学学士学位，在斯坦福大学获得工商管理硕士学位。
- Sharon Tetlow,has served as a member of Structure Therapeutics Inc. board of directors since March 2022. Since January 2016, Ms. Tetlow has served as Managing Partner of Potrero Hill Advisors, an advisory firm providing strategic and operational financial support to life sciences companies. Prior to Potrero Hill Advisors, Ms. Tetlow served as chief financial officer of several public and private biotech companies for the previous twenty years. Ms. Tetlow currently serves on the board of directors, on the nominating and governance committee and as chair of the audit committee of DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company, on the board of directors and as chair of the audit committee of Catalyst Biosciences, Inc. (Nasdaq: CBIO), a biopharmaceutical company, and on the supervisory board and as chair of the audit committee of Valneva SE (Nasdaq: VALN, EPA: VLA), a global commercial stage, public vaccine company. Ms. Tetlow received her B.S. in Psychology from the University of Delaware and her M.B.A. from Stanford University.
高管简历
中英对照 | 中文 | 英文- Thomas Lingelbach
Thomas Lingelbach，2013年起，担任本公司的总裁、首席执行官、管理委员会主席。加入我们之前，Lingelbach曾担任多种高级职务，最近担任Intercell AG的总裁兼首席执行官（从2006年到2013年公司与Vivalis SA合并）。在制药和疫苗行业的二十年中，他担任过各种国际责任递增的职位。他曾担任Chiron Behring GmbH&Co KG和Chiron Corporation全球工业运营疫苗Vice President的董事总经理。Chiron&8217；s被Novartis Vaccines&Diagnostics GmbH&Co KG收购后，他担任德国常务董事和总经理，直到加入Intercell。加入Intercell公司之前，他曾担任Novartis’；German Operations公司的总经理兼董事总经理。Lingelbach先生目前担任CMC HOOKIPA PharmaInc.董事会主席Lingelbach先生拥有Technische Hochschule Gieß；en/THM工程硕士学位。
Thomas Lingelbach has served as our President and Chief Executive Officer and Chairman of our Management Board since 2013. Prior to joining us, Mr. Lingelbach served in a variety of increasingly senior roles, most recently as President and Chief Executive Officer at Intercell AG from 2006 until its merger with Vivalis SA in 2013. He has held a variety of positions of increasing international responsibility in his twenty years in the pharma and vaccine industry. He has served as Managing Director of Chiron Behring GmbH & Co KG and Vice President, Global Industrial Operations-Vaccines of Chiron Corporation. Upon Chiron’s acquisition by Novartis Vaccines & Diagnostics GmbH & Co KG, he served as Managing Director and General Manager Germany until joining Intercell. Prior to joining Intercell, he was the General Manager and Managing Director for Novartis’ German operations. Mr. Lingelbach currently serves as president of the CMC Board of Hookipa Pharma Inc. Mr. Lingelbach holds an M.S. in Engineering from Technische Hochschule Gießen / THM.- Thomas Lingelbach，2013年起，担任本公司的总裁、首席执行官、管理委员会主席。加入我们之前，Lingelbach曾担任多种高级职务，最近担任Intercell AG的总裁兼首席执行官（从2006年到2013年公司与Vivalis SA合并）。在制药和疫苗行业的二十年中，他担任过各种国际责任递增的职位。他曾担任Chiron Behring GmbH&Co KG和Chiron Corporation全球工业运营疫苗Vice President的董事总经理。Chiron&8217；s被Novartis Vaccines&Diagnostics GmbH&Co KG收购后，他担任德国常务董事和总经理，直到加入Intercell。加入Intercell公司之前，他曾担任Novartis’；German Operations公司的总经理兼董事总经理。Lingelbach先生目前担任CMC HOOKIPA PharmaInc.董事会主席Lingelbach先生拥有Technische Hochschule Gieß；en/THM工程硕士学位。
- Thomas Lingelbach has served as our President and Chief Executive Officer and Chairman of our Management Board since 2013. Prior to joining us, Mr. Lingelbach served in a variety of increasingly senior roles, most recently as President and Chief Executive Officer at Intercell AG from 2006 until its merger with Vivalis SA in 2013. He has held a variety of positions of increasing international responsibility in his twenty years in the pharma and vaccine industry. He has served as Managing Director of Chiron Behring GmbH & Co KG and Vice President, Global Industrial Operations-Vaccines of Chiron Corporation. Upon Chiron’s acquisition by Novartis Vaccines & Diagnostics GmbH & Co KG, he served as Managing Director and General Manager Germany until joining Intercell. Prior to joining Intercell, he was the General Manager and Managing Director for Novartis’ German operations. Mr. Lingelbach currently serves as president of the CMC Board of Hookipa Pharma Inc. Mr. Lingelbach holds an M.S. in Engineering from Technische Hochschule Gießen / THM.
- Franck Grimaud
Franck Grimaud，2013年起，担任本公司的总裁、首席商务官、管理委员会成员。加入我们之前，他曾担任Vivalis SA公司的首席执行官（从1999年到2013年公司与Intercell AG公司合并）。Grimaud先生自2016年9月起担任Fonds Pays de la Loire Participations董事会主席，自2018年2月起担任Atlanpole Bioth&233；Rapies董事会总裁，2015年1月至2018年2月担任财务主管。Grimaud先生拥有渥太华大学（University of Ottawa）的工商管理硕士学位，并获得了Universit&233；de Poitiers的执照AES。
Franck Grimaud has served as our President and Chief Business Officer and as a member of our Management Board since 2013. Prior to joining us, he served as Chief Executive Officer of Vivalis SA from 1999 until its merger with Intercell AG in 2013. Mr. Grimaud has served as Chair of the Governing Board of Fonds Pays de la Loire Participations since September 2016 and as President of the Board of Directors of Atlanpole Biothérapies since February 2018 where he served as Treasurer from January 2015 to February 2018. Mr. Grimaud holds an M.B.A. from University of Ottawa and received his Licence AES from Université de Poitiers.- Franck Grimaud，2013年起，担任本公司的总裁、首席商务官、管理委员会成员。加入我们之前，他曾担任Vivalis SA公司的首席执行官（从1999年到2013年公司与Intercell AG公司合并）。Grimaud先生自2016年9月起担任Fonds Pays de la Loire Participations董事会主席，自2018年2月起担任Atlanpole Bioth&233；Rapies董事会总裁，2015年1月至2018年2月担任财务主管。Grimaud先生拥有渥太华大学（University of Ottawa）的工商管理硕士学位，并获得了Universit&233；de Poitiers的执照AES。
- Franck Grimaud has served as our President and Chief Business Officer and as a member of our Management Board since 2013. Prior to joining us, he served as Chief Executive Officer of Vivalis SA from 1999 until its merger with Intercell AG in 2013. Mr. Grimaud has served as Chair of the Governing Board of Fonds Pays de la Loire Participations since September 2016 and as President of the Board of Directors of Atlanpole Biothérapies since February 2018 where he served as Treasurer from January 2015 to February 2018. Mr. Grimaud holds an M.B.A. from University of Ottawa and received his Licence AES from Université de Poitiers.
- Juan Carlos Jaramillo
Juan Carlos Jaramillo自2020年10月起担任我们的首席医疗官和管理委员会成员。在加入我们之前，Jaramillo博士曾于2013年4月至2020年9月担任Daiichi Sankyo，GmbH的高级副总裁，市场准入和医疗事务，然后担任高级副总裁，全球市场准入和定价主管。在加入Daiichi Sankyo之前，Jaramillo博士曾担任GR&252；Nenthal，Inc.的高级副总裁，医疗事务与临床开发，在此之前曾在GlaxoSmithKline plc担任多个职位。Jaramillo博士在Universidad Central del Este获得医学预科的医学博士学位和工商管理硕士学位。
Juan Carlos Jaramillo has served as our Chief Medical Officer and as a member of our Management Board since October 2020. Prior to joining us, Dr. Jaramillo served as Senior Vice President, Market Access & Medical Affairs and then as Senior Vice President, Head of Global Market Access & Pricing at Daiichi Sankyo, GmbH from April 2013 to September 2020. Prior to Daiichi Sankyo, Dr. Jaramillo served as Senior Vice President, Medical Affairs & Clinical Development at Grünenthal, Inc. and prior to that held a variety of positions at GlaxoSmithKline plc. Dr. Jaramillo received his M.D. and B.S. in Pre-Medicine from Universidad Central Del Este.- Juan Carlos Jaramillo自2020年10月起担任我们的首席医疗官和管理委员会成员。在加入我们之前，Jaramillo博士曾于2013年4月至2020年9月担任Daiichi Sankyo，GmbH的高级副总裁，市场准入和医疗事务，然后担任高级副总裁，全球市场准入和定价主管。在加入Daiichi Sankyo之前，Jaramillo博士曾担任GR&252；Nenthal，Inc.的高级副总裁，医疗事务与临床开发，在此之前曾在GlaxoSmithKline plc担任多个职位。Jaramillo博士在Universidad Central del Este获得医学预科的医学博士学位和工商管理硕士学位。
- Juan Carlos Jaramillo has served as our Chief Medical Officer and as a member of our Management Board since October 2020. Prior to joining us, Dr. Jaramillo served as Senior Vice President, Market Access & Medical Affairs and then as Senior Vice President, Head of Global Market Access & Pricing at Daiichi Sankyo, GmbH from April 2013 to September 2020. Prior to Daiichi Sankyo, Dr. Jaramillo served as Senior Vice President, Medical Affairs & Clinical Development at Grünenthal, Inc. and prior to that held a variety of positions at GlaxoSmithKline plc. Dr. Jaramillo received his M.D. and B.S. in Pre-Medicine from Universidad Central Del Este.
- Frederic Jacotot
Frederic Jacotot自2013年以来一直担任我们的法律与IP and General Counsel Vice President，并自2017年4月以来一直担任我们的管理委员会成员。在加入我们之前，他从2010年到2013年担任雅培公司的法律顾问。Jacotot先生在巴黎第一潘斯大学（Paris1Panth&233；on-Sorbonne University）获得商法硕士学位。
Frederic Jacotot has served as our Vice President of Legal & IP and General Counsel since 2013 and has served on our Management Board since April 2017. Prior to joining us, he served as counsel at Abbott Laboratories from 2010 to 2013. Mr. Jacotot received his Diplôme d’études approfondies in business law from Paris 1 Panthéon-Sorbonne University.- Frederic Jacotot自2013年以来一直担任我们的法律与IP and General Counsel Vice President，并自2017年4月以来一直担任我们的管理委员会成员。在加入我们之前，他从2010年到2013年担任雅培公司的法律顾问。Jacotot先生在巴黎第一潘斯大学（Paris1Panth&233；on-Sorbonne University）获得商法硕士学位。
- Frederic Jacotot has served as our Vice President of Legal & IP and General Counsel since 2013 and has served on our Management Board since April 2017. Prior to joining us, he served as counsel at Abbott Laboratories from 2010 to 2013. Mr. Jacotot received his Diplôme d’études approfondies in business law from Paris 1 Panthéon-Sorbonne University.